Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,147,253
  • Shares Outstanding, K 96,031
  • Annual Sales, $ 129,160 K
  • Annual Income, $ -36,240 K
  • 60-Month Beta 2.13
  • Price/Sales 14.41
  • Price/Cash Flow N/A
  • Price/Book 4.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.49
  • Number of Estimates 6
  • High Estimate -0.14
  • Low Estimate -0.67
  • Prior Year 0.79
  • Growth Rate Est. (year over year) -162.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.02 +39.58%
on 01/03/20
23.21 -3.66%
on 01/15/20
+3.35 (+17.62%)
since 12/17/19
3-Month
14.24 +57.02%
on 10/18/19
23.21 -3.66%
on 01/15/20
+7.22 (+47.69%)
since 10/17/19
52-Week
14.24 +57.02%
on 10/18/19
28.86 -22.54%
on 04/10/19
+1.36 (+6.48%)
since 01/17/19

Most Recent Stories

More News
Novavax Rises on Fast Track Designation to Influenza Vaccine

The FDA bestows a Fast Track Designation on Novavax's (NVAX) influenza vaccine candidate NanoFlu for adults aged 65 years and older. Shares rally.

SNY : 51.24 (+0.10%)
EXAS : 88.06 (-1.92%)
NVAX : 5.74 (+20.08%)
DNLI : 22.36 (+1.13%)
Perrigo (PRGO) Rises on Stellar Q419 Preliminary Results

Perrigo (PRGO) announces better-than-expected preliminary results for fourth-quarter 2019 as well as the full year. Shares gain.

PRGO : 59.02 (-0.82%)
EXAS : 88.06 (-1.92%)
DNLI : 22.36 (+1.13%)
PETQ : 30.74 (-1.66%)
Denali Therapeutics Sees Hammer Chart Pattern: Time to Buy?

Denali Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

DNLI : 22.36 (+1.13%)
Emergent (EBS) Posts Preliminary '19 Results, Gives 2020 View

Emergent (EBS) narrows revenue view for 2019 and expects a consistent rise in Narcan nasal spray sales during 2020.

SNY : 51.24 (+0.10%)
GSK : 47.89 (+1.55%)
EBS : 55.56 (-0.86%)
DNLI : 22.36 (+1.13%)
Flagship Unveils Newest Pioneering Platform: Ring Therapeutics

Flagship Pioneering, a unique life sciences innovation enterprise, today announced the launch of Ring Therapeutics, an early-stage biotechnology company developing first-in-class gene therapies using a...

AXLA : 4.98 (+2.05%)
DNLI : 22.36 (+1.13%)
EVLO : 4.34 (+2.36%)
KLDO : 4.92 (-3.53%)
MRNA : 20.62 (-1.86%)
RUBY : 8.92 (-9.35%)
MCRB : 3.43 (-1.44%)
SYRS : 8.51 (-7.55%)
Flagship Pioneering Strengthens Leadership With Appointment of Paul Biondi as Executive Partner

Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Paul Biondi to the post of Executive Partner. Mr. Biondi most recently served as Senior Vice President,...

BMY : 66.72 (-0.09%)
AXLA : 4.98 (+2.05%)
DNLI : 22.36 (+1.13%)
EVLO : 4.34 (+2.36%)
KLDO : 4.92 (-3.53%)
MRNA : 20.62 (-1.86%)
RUBY : 8.92 (-9.35%)
MCRB : 3.43 (-1.44%)
SYRS : 8.51 (-7.55%)
Options Traders Expect Huge Moves in Denali (DNLI) Stock

Investors need to pay close attention to Denali (DNLI) stock based on the movements in the options market lately.

DNLI : 22.36 (+1.13%)
Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 Pioneering Leader Award

Flagship Pioneering has announced the recipient of the firm's annual Pioneering Leader Award. The 2019 award recognizes Nancy Simonian, M.D., CEO of Syros Pharmaceuticals (NASDAQ: SYRS), a company that...

AXLA : 4.98 (+2.05%)
DNLI : 22.36 (+1.13%)
EVLO : 4.34 (+2.36%)
KLDO : 4.92 (-3.53%)
MRNA : 20.62 (-1.86%)
RUBY : 8.92 (-9.35%)
MCRB : 3.43 (-1.44%)
SYRS : 8.51 (-7.55%)
Flagship Pioneering Appoints Prakash Raman, Ph.D. as Senior Partner and Chief Business Development Officer

Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Prakash Raman, Ph.D. to the post of Senior Partner and the newly created role of Chief Business Development...

NVS : 95.93 (+0.87%)
AXLA : 4.98 (+2.05%)
DNLI : 22.36 (+1.13%)
EVLO : 4.34 (+2.36%)
KLDO : 4.92 (-3.53%)
MRNA : 20.62 (-1.86%)
RUBY : 8.92 (-9.35%)
MCRB : 3.43 (-1.44%)
SYRS : 8.51 (-7.55%)
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Tops Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 9.43% and 25.24%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?...

DNLI : 22.36 (+1.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Trade DNLI with:

Business Summary

Denali Therapeutics Inc. is a biotechnology company. It focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and others. Denali Therapeutics Inc. is based in SOUTH SAN FRANCISCO,...

See More

Key Turning Points

2nd Resistance Point 23.15
1st Resistance Point 22.75
Last Price 22.36
1st Support Level 21.93
2nd Support Level 21.51

See More

52-Week High 28.86
Fibonacci 61.8% 23.28
Last Price 22.36
Fibonacci 50% 21.55
Fibonacci 38.2% 19.83
52-Week Low 14.24

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar